黑料官网

header-logo
GettyImages-758308167-hero
Biostatistics
Brent R. Logan, PhD

Brent R. Logan, PhD

Director & Professor, Biostatistics

Locations

  • Biostatistics

Contact Information

Education

PhD, Northwestern University, Evanston, IL, 2001
MS, Northwestern University, Evanston, IL, 1998
BS, Vanderbilt University, Nashville, TN, 1996

Research Experience

  • Multiple Comparison Procedures

Research Interests

Dr. Brent Logan joined biostatistics in the summer of 2001. He has methodological research interests in multiple comparison procedures, clinical trial design, and survival analysis. Research in multiple testing includes methods for analyzing multiple endpoints in clinical trials, analysis of dose-response studies, and multiplicity adjustment in functional MRI studies. His interests in clinical trial design include randomized phase 2 clinical trials and biologic assignment trials in bone marrow transplant studies. Recent work in survival analysis has focused on inference for competing risks and multistate models using pseudo-value regression, analysis in the presence of crossing survival curves, and methods for the analysis of complex bone marrow transplant data. He is a biostatistician for the and the , as well as a statistical consultant for the .

Publications

  • (Sorror ML, Saber W, Logan BR, Geller NL, Bellach A, Kou J, Wood WA, McCarty J, Knight TG, Runaas L, Johnston LJ, Walston JD, Nakamura R, Jarrett L, Mishra A, Uberti J, Dahi PB, Saultz JN, McCurdy SR, Morris LE, Imus P, Hogan WJ, Nadiminti KVG, Bhatt VR, Olin RL, Maakaron J, Sobecks RM, Wall SA, Mattila D, Protz B, Devine SM, Horowitz MM, Artz AS.) Blood Adv. 2025 Mar 18 PMID: 40101246 03/18/2025

  • (Kassim AA, Walters MC, Eapen M, Smith M, Logan BR, Solh M, McKinney C, Nieder M, Ross M, Kent M, Abusin GA, Mallhi K, Silva JG, Shaughnessy P, Kanter J, Haines H, Farah R, Khaled YA, Ritzau N, Mendizabal A, Abraham A, Bollard C, Cooke K, de la Fuente J, Hanna R, Horowitz MM, Jordan LC, Bakshi N, Krishnamurti L, Leifer E, Mahadeo KM, Shenoy S, Jones RJ, DeBaun MR, Brodsky RA.) NEJM Evid. 2025 Mar;4(3):EVIDoa2400192 PMID: 39998298 PMCID: PMC11932095 02/25/2025

  • (Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh MM, Mishra A, Muffly L, Kim HJ, Stelljes M, Najima Y, Onozawa M, Thomson KJ, Nagler A, Wei AH, Marcucci G, Chen C, Hasabou N, Rosales M, Hill JE, Gill SC, Nuthethi R, King D, Mendizabal AM, Devine SM, Horowitz MM, Chen YB.) Blood. 2025 Jan 07 PMID: 39775763 01/08/2025

  • (Khanal M, Logan BR, Banerjee A, Fang X, Ahn KW.) Pharm Stat. 2025;24(1):e2464 PMID: 39846144 SCOPUS ID: 2-s2.0-85216016393 01/23/2025

  • (Spellman SR, Sparapani R, Maiers M, Shaw BE, Laud P, Bupp C, He M, Devine SM, Logan BR.) Blood Adv. 2024 Dec 10;8(23):6082-6087 PMID: 39368807 PMCID: PMC11652765 SCOPUS ID: 2-s2.0-85212173730 10/06/2024

  • (Hamilton BK, Pandya BJ, Ivanescu C, Elsouda D, Hamadani M, Chen YB, Levis MJ, Ueda Oshima M, Litzow MR, Soiffer RJ, Ustun C, Perl AE, Singh AK, Geller N, Hasabou N, Rosales M, Cella D, Corredoira L, Pestana C, Horowitz MM, Logan B.) Blood Adv. 2024 Oct 08;8(19):5091-5099 PMID: 39167766 PMCID: PMC11460446 SCOPUS ID: 2-s2.0-85206267504 08/21/2024

  • (Pasquini MC, Wallace PK, Logan B, Kaur M, Tario JD, Howard A, Zhang Y, Brunstein C, Efebera Y, Geller N, Giralt S, Hari P, Horowitz MM, Koreth J, Krishnan A, Landau H, Somlo G, Shah N, Stadtmauer E, Vogl DT, Vesole DH, McCarthy PL, Hahn T.) J Clin Oncol. 2024 Aug 10;42(23):2757-2768 PMID: 38701390 PMCID: PMC11634105 SCOPUS ID: 2-s2.0-85201029574 05/03/2024

  • (Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB, BMT-CTN 1506/MORPHO Study Investigators.) J Clin Oncol. 2024 May 20;42(15):1766-1775 PMID: 38471061 PMCID: PMC11095884 SCOPUS ID: 2-s2.0-85193456124 03/12/2024

  • (Sparapani RA, Maiers M, Spellman SR, Shaw BE, Laud PW, Devine SM, Logan BR.) medRxiv. 2024 May 09 PMID: 38766030 PMCID: PMC11100939 05/20/2024

  • (Grunebaum E, Arnold DE, Logan B, Parikh S, Marsh RA, Griffith LM, Mallhi K, Chellapandian D, Lim SS, Deal CL, Kapoor N, Murguía-Favela L, Falcone EL, Prasad VK, Touzot F, Bleesing JJ, Chandrakasan S, Heimall JR, Bednarski JJ, Broglie LA, Chong HJ, Kapadia M, Prockop S, Dávila Saldaña BJ, Schaefer E, Bauchat AL, Teira P, Chandra S, Parta M, Cowan MJ, Dvorak CC, Haddad E, Kohn DB, Notarangelo LD, Pai SY, Puck JM, Pulsipher MA, Torgerson TR, Malech HL, Kang EM, Leiding JW.) J Allergy Clin Immunol. 2024 May;153(5):1423-1431.e2 PMID: 38290608 PMCID: PMC11070290 SCOPUS ID: 2-s2.0-85185611997 01/31/2024

  • (Martens MJ, Logan BR.) Clin Trials. 2024 Apr;21(2):152-161 PMID: 37877375 PMCID: PMC11003847 SCOPUS ID: 2-s2.0-85174803819 10/25/2023

  • (Martens MJ, Lian Q, Geller NL, Leifer ES, Logan BR.) Clinical Trials. 2024 SCOPUS ID: 2-s2.0-85213536554 01/01/2024

Publications of from the

© 2025 黑料官网.  All rights reserved.  | Terms and Privacy | Web Accessibility Statement

Non-Discrimination Statement
The 黑料官网 (黑料官网) is committed to fostering a diverse community of outstanding faculty, staff, and students, as well as ensuring equal educational opportunity, employment, and access to services, programs, and activities, without regard to an individual's race, color, national origin, religion, age, disability, sex, gender identity/expression, sexual orientation, marital status, pregnancy, predisposing genetic characteristic, or military status. Employees, students, applicants or other members of the 黑料官网 community (including but not limited to vendors, visitors, and guests) may not be subjected to harassment that is prohibited by law or treated adversely or retaliated against based upon a protected characteristic. 黑料官网’s policy as well as federal and state laws and regulations prohibit unlawful discrimination and harassment.

Notice of Compliance with Laws and Commitment to Civil Rights
The 黑料官网 is committed to full compliance with all applicable federal, state, and local laws and regulations in the pursuit of our missions. Consistent with recent federal guidance, we affirm our commitment to individual merit, fairness, and equal treatment in all aspects of academic and institutional decision-making. As part of this commitment, we are actively reviewing our policies and materials to ensure they align with federal nondiscrimination obligations.